Fig. 6From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysisNetwork comparisons for interventions included in the analysis. Second part of the network: A: PFS; B: OS; C: ORR; D: SAE. Third part of the network: E: PFS; F: OS; G: ORRBack to article page